Tuesday, May 7, 2013

Adverse Drug Reactions and Drug Interactions.


ADVERSE DRUG REACTIONS:
Definition : Adverse Reaction:
“Any response that is noxious and unintended that occur at the doses used for diagnosis, prevention and treatment of disease.”

Drug toxicity may come in many forms:
  1. Acute versus chronic,
  2. Mild versus severe,
  3. Predictable versus unpredictable,
  4. Local versus systemic.
Administration of drug may result in:
          Side effects.
          Untoward effects.
          Toxic effects.

Definition:
Pharmacological effects of drug produced at therapeutic doses that depending upon the condition; may be desirable or undesirable.
For example :
Atropine produces dryness of mouth.
          Dryness of mouth is side effect when atropine is used for treatment of sinus bradycardia,
          but it is desirable when atropine is used as preanesthetic medication.

UNTOWARD EFFECTS:
Undesirable effects produced at therapeutic doses, when severe enough, necessitate cessation of drug therapy.
For example: Hypokalemia produced by loop diuretics.

TOXIC EFFECTS:
          produced when drug is repeatedly administered or given in large doses.
               
For example :
Respiratory depression produced by morphine.

Important systemic adverse effects:

DRUG INTOLERANCE:
Inability to tolerate the drug.
Drug intolerance may be:
A. Quantitative.                       
B. Qualitative
                a) Idiosyncrasy.
                b) Hypersensitivity (Allergy).

QUANITATIVE INTOLERANCE:
          Some persons show increased response to therapeutic or even smaller doses of the drugs such people are called “HYPER REACTORS.”      
For example:
      G.I bleeding and vomiting with single dose of salicylates.

QUALITATIVE INTOLERANCE:
IDIOSYNCRASY:
          Unusual individual response to certain drugs due to deficiency or complete lack of certain enzymes in drug recipient.
                                                                                OR
          Genetically controlled abnormal reaction to a drug..
For example:
     Hemolysis produced by Primaquine and Sulfonamides in patients with G.6.P.D deficiency.

HYPERSENSITIVITY (ALLERGY):
          Exaggerated sensitivity to certain foreign substances which are harmless to great majority of population. It has an immunological basis.
          Allergy can be distinguished from other forms of drug toxicity in some respects
First, prior exposure to drug or closely  related compound.
Second, intensity of response is  usually dose independent.
Third usually similar signs and symptoms produced irrespective  of the drug used .
Drugs commonly producing allergic reactions are:
                          Penicillins,
                          Sulfonamides,
                          Quinidine,
                          Insulin,
                          Dextran.
  
4 groups of allergic reactions:
TYPE-I:
          Immediate form of allergy
          disturbances appear within minutes or hours.
          Immune reaction is initiated by attachment of antigen to IgE antibodies to surface of mast cells and basophils.
         Rupture of these cells liberates histamine and other mediators of inflammation.
          Major signs and symptoms are erythema, urticaria, itching, broncho-constriction, edema, abdominal cramps and diarrhea.

Anaphylaxis:
Severe form of type-I reaction.
          Life threatening reactions are common with parenteral drug injection than oral or topical drug application.
          Epinephrine reverse the manifestation of severe reactions;
          Antihistamines and Corticosteroids are also useful.

TYPE-II Reactions:
          Mediated by circulating IgG.
          usually delayed responses from several hours to days after drug exposure.
Examples:
          Drug induced hemolysis,
          leukopenia and
           thrombocytopenia.
TYPE-III:
          immune complexes are formed between antigen & antibody.
          deposited in small blood vessels or within interstitial spaces resulting in activation of complement cascade that attract neutrophils.
          lysosomal enzymes liberated by neutrophils cause local tissue damage and promote thrombosis of affected blood vessels.
TYPE-IV:
          mediated by sensitized T lymphocytes.
          usually delayed .


G.I.T DISTURBANCES:
          Many drugs produce gastrointestinal disturbances. Like;
          Nausea and vomiting by digitalis, morphine, anticancer drugs.
          Constipation by opioids, verapamil and antidiarrheal agents
Diarrhea by colchicine and purgatives.

HEMOPOETIC TOXICITY:

ANEMIA:
          Chloramphenicol,
          Primaquine,
          Methyldopa,
          Sulfonamides.   

LEUKOPENIA:
          Phenylbutazone,
          Thiouracil,
          Chlorpromazine,
          Imipramine
          Chloramphenicol.
           
THROMBOCYTOPENIA.
          Quinidine,
          Tolbutamide,
          Digitalis
          Rifampin.

BLEEDING:
          Aspirin,
          Corticosteroids,
          Heparin
          Warfarin.
HEPATOTOXICITY:
                Direct:
          Isoniazid,
          Tetracycline and Halothane.   
Immunological:
          Isoniazid,
          Rifampin,
          Pyrazinamide,
          Methyldopa,
          Indomethacin and chlorpromazine.
NEPHROTOXICITY:
          Aminoglycosides,
          Amphotericin B,
          Vancomycin,
          Bacitracin,
          Polymyxins,
          Sulfonamides,
          Hydralazine,
          Pencillamine,
          Phenacetin and Acetaminophen.

BEHAVORIAL TOXICITY:

Reserpine:           Suicidal tendencies.
Amphetamine:     Disorientation, Confusion
Glucocorticoids:  Euphoria.

ELECTROLYTE DISTURBANCES:
          Hypokalemia:                   
                               Diuretics.
          Hypernatremia:               
          Carbenoxolone,                    
          Corticosteroids.

ENDOCRINE DISTURBANCES:
Chlorpromazine:               Menstrual irregularities.
Oral contraceptives:         Suppression of  lactation.
Corticosteroids:                Hyperglycemia
Cimetidine:                        Gynecomastia.
Ketoconazole:                   Gynecomastia.
Lithium carbonate:           Goiter.

SKIN TOXICITY:
                Skin rashes (Urticaria) by
          PENICILLINS,
          CEPHALOSPORINS,
          AMIODARONE
          CLOFAZEMINE,
          SULFONAMIDES AND TETRACYCLINES.
CARCINOGENESIS:
          Estrogens produce breast and endometrial cancer;
          reserpine produces breast cancer,
          metronidazole is mutagenic and produces tumors.

TERATOGENICITY:
          Some drugs produce developmental abnormalities in fetus (teratogenic effect) like phocomalia by thalidomide, cleft palate by phenytoin.when these drugs administered during pregnancy.
DRUG DEPENDENCE:
          Certain drugs when used repeatedly may make the individual psychologically and physiologically dependent upon the drug i.e. discontinuation of drug may produce withdrawal syndrome.
          Morphine alcohol and cocaine can produce drug dependence.
UNMASKING OF DISEASE:
          Thiazides and corticosteroids unmask diabetes mellitus, and epilepsy is unmasked by isoniazid.
IATROGENIC EFFECT:
          Disease produced physician through the use of certain drugs is called iatrogenic effect.
                For example:
          Parkinson’s disease produced by antipsychotic drugs,
          peptic ulcer by NSAIDs.

DEFINITION;
               
It is the modification of the effect of one drug (the object drug ) by the prior concomitant administration of another (precipitant drug).

OUTCOMES OF DRUG INTERACTIONS
  1. Loss of therapeutic effect
  2. Toxicity
  3. Unexpected increase in pharmacological activity
  4. Beneficial effects  e.g additive  & potentiation (intended) or antagonism (unintended).
  5. Chemical or physical interaction e.g I.V incompatibility in fluid or syringes mixture

STORAGE CONDITIONS:
Pharmacokinitics
involve the effect of a drug interaction from point of view that includes absorption ,distribution , metabolism and excretion.
Pharmacodynamics
are related to the pharmacological activity of the interacting drugs e.g synergism.antagonism, altered cellular transport, effect on the receptor site. 
Drug interactions: Pharmacodynamic and Pharmacokinetic
Pharmacodynamic Interaction
Drug A alters the effect of Drug B without a change in the concentration of Drug B Pharmacokinetic Interaction
Drug A alters the effect of Drug B by changing the plasma concentration of Drug B
Pharmacokinetic interactions
1) Altered GIT absorption.
          Altered pH, Altered bacterial flora, formation of drug chelates or complexes, drug induced mucosal damage and altered GIT motility.
          Altered pH;
          The non-ionized form of a drug is more lipid
          soluble and more readily absorbed from GIT
          than the ionized form does.  

ENZYME INHIBITION:
It is the decrease of the rate of metabolism of a drug by another one.This will lead to the increase of the concentration of the target drug and leading to the increase of its toxicity
Inhibition of the enzyme may be due to the competition on its binding sites , so the onset of action is short may be within 24h.
First-pass metabolism
Oral administration increases the chance for liver and GIT metabolism of drugs leading to the loss of a part of the drug dose decreasing its action. This is more clear when such drug is an enzyme inducer or inhibitor

RENAL EXCRETION
          Active tubular secretion;
It occurs in the proximal tubules (a portion of renal tubules). The drug combines with a specific protein to pass through the proximal tubules.

PREVENTION OF DRUG INTERACTION
1)      Monitoring therapy and making adjustments
2)      Monitoring blood level of some drugs with narrow
                 therapeutic index e.g., digoxin, anticancer agents…etc
3) Monitoring some parameters that may help to
                characterize the the early events of interaction
                or toxicity e.g., with warffarin administration, it
                is recommended to monitor the prothrombin time
                to detect any change in  the drug activity.
Main offenders :
Light  (sodium nitroprusside)
water  (aspirin)
Air  (oxidation of drug)
drug Interactions: Outside Body
Mechanisms of drug interactions


Things to Remember
  • Interactions are easily forgotten when prescribing
  • Interactions are difficult to remember
  • Pharmacodynamic interactions can often be predicted across drug classes
  • Pharmacokinetic interactions can not be predicted – experiments needed
  • Many interactions probably remain undescribed – so look out for them
  • The chances of interaction are 60 times higher in a patient taking 5 drugs than in one taking 2. 
USE OF DRUGS IN PREGNANCY:

·         The FDA to indicate the Potential of  systemically absorbed  drugs for causing birth defects; establishes five pregnancy categories:

CATEGORY A:

·         Controlled studies in the pregnant women fail to demonstrate a risk to the fetus in first trimester with no evidence of risk in later trimesters.
·         The possibility of fetal harm is remote
o   Examples:
o   INSULIN,
o   VITAMIN B,
o   VITAMIN D,
o   PARACETAMOL..

CATEGORY B:

·         Either animal reproduction studies have not demonstrated fetal risk but there are no controlled studies in pregnant women OR animal reproduction.
·         Studies shown an adverse effect (Not Teratogenic) that was not confirmed in controlled studies in women, in the first trimester and there is no evidence of risk in later trimesters.
o   Example:
o   RABEPRAZOLE, AMOXICILLIN, METOPROLOL, METHYLDOPA.

CATEGORY C:

·         Either studies in animals have revealed adverse effects on fetus (Teratogentic) and there are no controlled studies in women,                                                                          OR
o   Studies in women and animals are not available.
·         Drug should be given only if the potential benefits justify the potential risk to the fetus.
o   Examples:
o   ACETAZOLAMIDE,
o   OMEPRAZOLE,
o   ACYCLOVIR.

CATEGORY D:

·         There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk e.g. if the drug is needed in the life-threatening situations or for a serious disease for which safer drugs are ineffective.
·         Examples:
o   DIAZEPAM,
o   METHOTREXATE,
o   PHENYTOIN.

CATEGORY X:

·         Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal risk based on human experience, or both, and the risk of use of drug in pregnant women clearly outweighs any possible benefit. The drug is strictly contraindicated in women who are pregnant.
o   Examples:
o   DOXORUBICIN,
o   SIMVASTATIN,
o   TESTOSTERONE.    



Drug-induced gingival enlargement


Introduction
Drug-induced gingival enlargement is classified by the American Academy of Periodontology as a dental plaque-induced gingival disease,  as evidence suggests that existing gingival inflammation may be necessary for its development and that proper plaque control and effective oral hygiene can lessen its severity or potentially prevent its occurrence altogether. 2 Currently, there are over 20 medications from three pharmaceutical categories including anticonvulsants, calcium channel blockers and immunosuppressants that are associated with gingival enlargement.4  It is the responsibility of the dental practitioner to recognize the potential of these medications to contribute to gingival enlargement and to provide the proper prophylactic care or appropriately refer the patient for periodontal therapy.  A team approach involving a consultation with a periodontist and the patient’s physician is a critical step in successful treatment.

Risk factors
During a course of treatment with a medication implicated in the pathogenesis of drug-induced gingival enlargement, poor plaque control is the most significant risk factor associated with its development.  The severity of enlargement is often proportional to the amount of gingival inflammation present and not the dosage of medication.  Overall, males tend to be affected three times as often as females and age is inversely correlated with likelihood of occurrence.

Medication
Prevalence of gingival enlargement with phenytoin (Dilantin®) use has been shown to be up to 50%, while other anticonvulsants such as valproic acid, Phenobarbital® and Tegretol® have been shown to be rarely associated with the disorder.  Of the calcium channel blockers, nifedipine (Adalat®, Procardia®) and diltiazem (Cardizem®) are the most likely to cause gingival enlargement (5-20%) while amlodipine (Lotrel®, Norvasc®), felodipine (Aggon®, Plendil®) and verapamil (Calan®, Covera®) are far less likely to be implicated.  Cyclosporin A, an immunosuppressant commonly used in organ transplant patients, has been shown to be associated in 25-30% of adult patients and over 70% in children, while tacrolimus has a significantly lower association at 14%.

Pathogenesis
While the physiology behind drug-induced gingival enlargement has not been definitively elucidated, histopathologic studies have shown that the gingival tissue volume increase is due to an excessive accumulation of extracellular matrix proteins including collagen and ground substance with a predominance of plasma cells.  Hence, the increase in tissue volume is primarily a connective tissue response and not epithelial.  Recent evidence suggests that this overgrowth could occur not from over-production of collagen, but rather through prolonged cell life of keratinocytes.  Another hypothesis is that fibroblasts in susceptible patients are sensitive to the medication in question, causing increased protein, and hence collagen, production.

Clinical presentation
Clinically, gingival enlargement frequently appears within 1-3 months of the initiation of treatment with the offending medication. The facial surfaces of the gingiva in anterior sextants are often most severely involved, and the patient may present with inflamed, fibrotic masses spreading from the interdental papillae to the attached gingiva that may interfere with mastication, speech and esthetics.  Due to discomfort secondary to inflammation and the physical topography of the enlarged gingiva, oral hygiene may be impaired and diet can be adversely affected.  This can lead to a host of other problems including caries, periodontal disease and immunosuppression secondary to malnutrition.

Treatment and prevention
Meticulous oral hygiene and plaque control combined with the removal of local factors are essential for any patient taking drugs associated with gingival enlargement.  A three-month periodontal maintenance interval is strongly recommended as well.  While excellent oral hygiene and professional plaque control can potentially prevent or lessen the severity of the condition, they often are insufficient for reversing the process once established.  It is therefore prudent to consult the patient’s physician to discuss potential drug substitutions that may result in regression of the lesions with proper supportive periodontal care and oral hygiene.  After drug substitution or withdrawal, evidence suggests that gingival lesions may resolve in 1-8 weeks in some patients.In transplant patients, however, drug substitution or cessation may not be an option due to the risk of transplant rejection.  Treatment of gingival enlargement in patients taking cyclosporin A should focus on their chronically immunosuppressed state.  In these patients, evidence suggests that topical antifungal treatment such as Nystatin lozenges, chlorhexidine rinses or a short course of azithromycin (3-5 days; 200-500 mg/day) can be effective.  There is evidence that systemic azithromycin remains effective in reducing gingival overgrowth from three months to two years after treatment, but this data is controversial.  A topical treatment including scaling and root planing in conjunction with an azithromycin-containing toothpaste used twice daily for one month has been shown to be effective in reducing gingival overgrowth as well, but the long-term efficacy of this treatment is unclear.

If the patient has gingival overgrowth and is currently taking:
Discuss the following substitution with the primary care provider:
Nifedipine
(6-15%)
Isradipine, Amlodipine, Verapamil, Felodipine
Phenytoin
(50%)
Carbamazepine, Valproic Acid, Vigabatrin, Phenobarbitone
Cyclosporin A
(Adults 25-30%,
Children >70%)
Tacrolimus
Note: incidence of gingival enlargement in parentheses.  Table adapted from Dongari-Bagtzoglou 2004.

While non-surgical therapy and, if possible, drug substitutions should be attempted first, surgery is often necessary to fully correct the esthetic and functional impairment encountered in this disorder.  Surgical excision has been successful in non-responding nifedipine cases when combined with good oral hygiene as well as in cases associated with verapamil and diltiazem, but it does tend to recur.A classic external bevel gingivectomy is an option to reduce redundant tissue.  An internal gingivectomy approach, however, has been advocated due to its ability to provide primary closure and reduce the incidence of postoperative bleeding, discomfort and infection.  Due to its technical difficulty, this procedure may be best referred to a periodontist.  Another surgical option is the CO2 laser due to its decreased surgical time, rapid hemostasis and its compatibility with a host of underlying medical conditions.

Recurrence
Eighteen months after surgical therapy, the recurrence rate of gingival overgrowth in patients taking cyclosporin A or nifedipine was 34% in a study of 38 individuals.  Age, gingival inflammation and attendance at recall visits are all significantly related to recurrence.  To help prevent recurrence post-surgically, chlorhexidine rinse twice daily is recommended.

Conclusion
Drug-induced gingival enlargement is a common sequela to treatment with anticonvulsants, calcium channel blockers and immunosuppressants.  Evidence suggests that gingival inflammation is critical in its pathogenesis.  While it may be prevented through meticulous periodontal maintenance and home care, it is essential for the dentist to work together with the patient’s physician and periodontist in order to successfully treat this condition once it occurs.

Thursday, May 2, 2013

Oral Health and Pregnancy



What is the public health issue?
Oral disease, particularly periodontal (gum) disease, may be related to premature and low birth-weight babies. Pregnant women with periodontal disease may be seven times more likely to have a baby that's born too early and too small, which can result in serious health problems that can be life-long. The exact connection between periodontal disease and preterm birth is unknown, but it might be due to inflammation (swelling) inside the body, the transfer of bacteria from the mouth into the placenta or amniotic fluid, or the release of a particular chemical that stimulates contractions (prostaglandin) from the mouth into the body. Pregnant women should take good care of their teeth and gums by brushing two times every day for two minutes, and flossing daily. They are at an increased risk for gum problems, as almost half of pregnant women in their second or third month of pregnancy get pregnancy gingivitis—this causes gum swelling, pain, and bleeding. In some cases, gums swollen by pregnancy gingivitis can form large growths, called “pregnancy tumors.” They are not cancerous and generally painless. However, if a tumor does not go away, it may need to be removed by a dentist. Pregnant women should also be educated about protecting their new baby’s oral health. Bacteria that cause tooth decay can spread from Mother and Child, and this increases the child’s risk for tooth decay in the future. Mothers should avoid sharing forks, spoons, and drinks with their babies.
Pregnency and oral health

Oral Health Before and During Pregnancy

  • Drink fluoridated water
  • Brush your teeth and gums twice a day with a fluoride toothpaste and floss each day
  • Make an appointment for an exam with a dentist
  • Make good nutritional choices; limit sweet drinks and avoid sugar
  • Include Vitamin C and Calcium in your daily diet
  • Do not smoke
  • Get plenty of rest
  • Learn how to take care of the baby’s gums and teeth even before birth


Infant and Toddler Oral Health Tips
  • Consult a pediatrician or family physician on the best water to use with infant formula.
  • Start oral care early. Begin by wiping the baby’s gums with a cloth or gauze after feeding.
  • Start brushing as soon as the first tooth appears.
  • When the child can brush on his or her own, supervise brushing to make sure fluoride toothpaste is not being used in large amounts and swallowed by the child.
  • Try to schedule the child’s first dental visit around his or her first birthday.

Popular Posts

Join This site